Non-Haemolytic Friulimicins for the Treatment of Multi-Drug Resistant Bacteria

我们正在开发一种名为弗留利霉素的新抗生素，以对抗在医院和社区造成严重感染的超级细菌。我们将优化药物以靶向MRSA（耐甲氧西林金黄色葡萄球菌）、VRE（耐万古霉素肠球菌）和DRSP（耐药肺炎链球菌）。我们还将研究该药物如何用于治疗肺炎等肺部感染，其中抗生素可以比现有药物更好地对抗耐药细菌。

We are developing a new antibiotic, called friulimicin, to combat the ïsuperbugsÍ that cause serious infections in hospitals and the community. We will optimize the drug to target MRSA (methicillin resistant Staphylococcus aureus) VRE (vancomycin resistant enterococci) and DRSP (drug resistant Streptococcus pneumoniae). We will also investigate how the drug can be used for treatment of lung infections such as pneumonia, where the antibiotic can work much better than existing drugs against resistant bacteria.